
The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a squabble with Novo Nordisk that had resulted in lawsuits.

The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a squabble with Novo Nordisk that had resulted in lawsuits.
UNITED ARAB EMIRATES — (ARAB NEWSWIRE) — Techjockey, a leading B2B software discovery and procurement…
California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…
Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…
The acquisition helps diversify UCB’s small molecule-centric arsenal of seizure treatments with a potentially one-off therapy in early testing for…
I spent last week in Amsterdam, attending HLTH Europe 2026, arguably Europe's flagship healthcare innovation event, hosting more than 5,000…
IL2RG protein, encoded by tL2RG complementary DNA. (https://commons.wikimedia.org/wiki/File:Protein_IL2RG_PDB_2b5i.png) As reported in the 18 April issue of the New England Journal…
Sarepta and Roche will share the monitors' findings with EMA to resolve a temporary hold. Elsewhere, Allakos agreed to a…
Sign in to your account